StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)

StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report released on Thursday. The brokerage set a “sell” rating on the stock.

MBRX has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Moleculin Biotech in a research report on Monday, March 3rd. Maxim Group downgraded Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.

Moleculin Biotech Trading Down 2.6 %

NASDAQ MBRX opened at $1.13 on Thursday. The business’s 50-day moving average price is $1.42 and its 200 day moving average price is $2.07. Moleculin Biotech has a twelve month low of $0.40 and a twelve month high of $8.85.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.